Best of ASH-2016 & 21st Annual CME in Hematology

With International faculty

Thurs-Sat, 19th - 21st Jan, 2017
Hotel ITC Grand Central, Parel, Mumbai, India
Executive Committee
Mumbai Hematology Group

President
Dr. M.B. Agarwal

Vice-President
Dr. Farah Jijina

Secretary
Dr Swati Kanakia

Treasurer
Dr. Brijesh Arora

Members
Dr Shubhangi Agale
Dr. S.D. Banavali
Dr. Roshan Colah
Dr. Mukesh Desai
Dr. S. Khodaiji
Dr. Vrinda Kulkarni
Dr. Mamta Manglani
Dr. Navin Khattry
Dr. Chandrakala S
Dr. Asha Shah
Dr Shrimati Shetty

With compliments from
Dear Colleague,

Best of ASH-2016 (which will be held in San Diego in December 2016) and 21st Annual CME in Hematology will be held under the aegis of Mumbai Hematology Group (MHG) at Hotel ITC Grand Central, Parel, Mumbai from Thursday to Saturday, 19th to 21st January 2017.

We have already engaged some of the top international faculty from US and Europe for this event. Emphasis will be on the newer data that will be presented during ASH-2016. We will be discussing both basics as well as applied aspects (Diagnostic and Therapeutic). Pediatric subjects will also be covered.

As usual, Team from Nucleus (Mr. Rajesh Sharma, Mr. Yash Agarwal, Mr. Kalpesh Pambhar and others) has been appointed for managing the event.

The meeting will begin with lunch on day 1 and end with lunch on day 3. You can arrive in the morning of day 1 and leave by late afternoon on day 3. A large number of rooms have been booked at same hotel for 2 nights i.e. Thursday and Friday (19th & 20th of January 2017).

Early registration for this event will be the key to make it an economical affair.

Looking forward to your kind participation which will make this academic feast a grand event.

Your sincerely

Dr M B Agarwal, MD
Hematologist & Hemato-Oncologist
President - Mumbai Hematology Group

Mumbai Hematology Group
Best of ASH-2016 & 21st Annual CME in Hematology

International faculty

**Dr. Flora Peyvandi, MD, PhD**
Professor of Internal Medicine  
Director of the Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre  
Fondazione IRCCS Ca’ Granda  
Ospedale Maggiore Policlinico  
Milan, Italy

**Dr. Sabine Eichinger**
Professor of Medicine  
Department of Internal medicine  
Medical University of Vienna  
Karl Landsteiner Institute of Thrombosis Research,  
Vienna, Austria

**Dr Henrik Hasle**
Professor  
Department of Paediatrics,  
Aarhus University Hospital Skejby,  
Aarhus, Denmark

**Dr Ajay Nooka**
Assistant Professor  
Division of Bone Marrow Transplant  
Department of Hematology and Medical Oncology,  
Winship Cancer Institute of Emory University,  
Atlanta, Georgia, USA
Dr. Naval Daver
Assistant Professor
Leukemia Department
MD Anderson Cancer Center
Houston, Tx, USA

Dr. Ghulam Mufti
Director of King's College Hospital NHS Foundation Trust
Professor of Haemat-oncology,
Clinical Director of Pathology
Head of the Department of Haematology
King's College Hospital, London, UK

John Mascarenhas, MD
Tisch Cancer Institute, Division of Hematology/Oncology
Icahn School of Medicine at Mount Sinai
New York, USA

Dr A C Newland
Professor
Department of Haematology
Barts Health NHS trust - The Royal London Hospital
London, UK
Best of ASH-2016 & 21st Annual CME in Hematology

International faculty

Dr Neal Young, MD
Senior Investigator
Cell Biology Section, Hematology Branch
National Heart, Lung and Blood Institute
National Institutes of Health, Bethesda, MD, USA

Dr Genoveffa Franchini, MD
Center for Cancer Research
National Cancer Institute (NCI)
National Institutes of Health
Bethesda, MD, USA

Dr Mala K Talekar, MD
Attending Physician, Cancer Immunotherapy Frontier Program
Division of Oncology & Blood and Marrow Transplantation
Department of Pediatrics
The Children’s Hospital of Philadelphia,
Philadelphia, USA
Best of ASH-2016 & 21st Annual CME in Hematology

Who will speak on what!

Dr Ajay K Nooka
1. Definition and management of high risk myeloma: progress in the last decade
2. Newer Therapeutic options for R/R myeloma: focus on Carfilzomib
3. ASH 2016 updates in myeloma

Dr Ghulam Mufti
1. Low risk MDS - What is new?
2. High risk MDS - What is new?
3. Pathobiology of MDS - What is new?

Dr Naval Daver
1. A Look at Immunotherapeutic Drug Development in leukemia and MDS: 2017
2. AML: Highlights of Molecular and Immune Therapies from ASH 2016
3. The future of Hypomethylating Agents in AML: Building Optimal Combinations

Dr John Mascarenhas
1. Ruxolitinib the past, present and what to expect in the future
2. Case based clinical approach to modern management of ET, PV and PMF, as well as MPN related AML
3. Updates on MPN from ASH 2016

Dr Hasle Henrik
1. Myelodysplastic and Myeloproliferative Disorders of Childhood
2. Management of childhood AML
3. Late complications in survivors of AML

Dr Mala Talekar
1. Chimeric Antigen Receptor (CAR) Modified T cell Therapy for relapsed / refractory pediatric leukaemias

Dr Neal Young
1. Immunology of acquired aplastic anemia: pathophysiology and treatment
2. Telomere disease and other constitutional marrow failure syndromes in adults
3. Eltrombopag as stem cell stimulation in bone marrow failure

Dr A C Newland
1. How do I treat ITP in 2017?
2. A to Z about Romiplostim in the treatment of ITP
3. Platelets: What was new in ASH-2016?

Dr Flora Peyvandi
1. Thrombotic thrombocytopenic purpura - Advances
2. Hemophilia: Diagnosis, treatment and complications - The past and future
3. Bleeding disorders - Advances in treatment

Dr Sabine Eichinger
1. All about DOACs
2. Recurrent DVT - All that a clinician should know
3. Cancer related thrombosis

Dr Gnoveffa Fanchini
1. From animal studies to men and back: Prospective in the development of a vaccine for HIV
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Subject</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00 am onwards</td>
<td>Registration</td>
<td></td>
</tr>
<tr>
<td>09.00 am - 09.45 am</td>
<td>Meet the professor</td>
<td>Marrow failure syndromes (Neal Young)</td>
</tr>
<tr>
<td>10.00 am - 10.45 am</td>
<td>Meet the professor</td>
<td>AML, MDS, MPN (Naval Daver)</td>
</tr>
<tr>
<td>11.00 am - 11.45 am</td>
<td>Meet the professor</td>
<td>Bleeding &amp; Thrombotic Disorders (Flora Peyvandi &amp; Sabine Eichinger)</td>
</tr>
<tr>
<td>12.00 noon</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>12.45 pm - 01.00 pm</td>
<td>Opening ceremony</td>
<td>Purvish Parikh, Sudeep Gupta, Shashi Apte, Jina Bhattacharya</td>
</tr>
<tr>
<td>01.00 pm - 01.30 pm</td>
<td>Neal Young, USA</td>
<td>Immunology of acquired aplastic anaemia: Pathophysiology and treatment</td>
</tr>
<tr>
<td>01.30 pm - 02.00 pm</td>
<td>Naval Daver, USA</td>
<td>A Look at Immunotherapeutic Drug Development in leukemia and MDS: 2017</td>
</tr>
<tr>
<td>02.00 pm - 02.30 pm</td>
<td>Gnoveffa Fanchini, USA</td>
<td>From animal studies to men and back: Prospective in the development of a vaccine for HIV</td>
</tr>
<tr>
<td>02.30 pm - 02.45 pm</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>02.45 pm - 03.15 pm</td>
<td>Coffee</td>
<td></td>
</tr>
<tr>
<td>03.15 pm - 03.45 pm</td>
<td>Sabine Eichinger, Vienna</td>
<td>Cancer related thrombosis- Advances</td>
</tr>
<tr>
<td>03.45 pm - 04.15 pm</td>
<td>Flora Peyvandi, Italy</td>
<td>Thrombotic thrombocytopenic purpura - Advances</td>
</tr>
<tr>
<td>04.15 pm - 04.45 pm</td>
<td>Sabine Eichinger, Vienna</td>
<td>All about DOACs in 2017</td>
</tr>
<tr>
<td>04.45 pm - 05.15 pm</td>
<td>Flora Peyvandi, Italy</td>
<td>Hemophilia : Diagnosis, treatment &amp; complications - The past &amp; future</td>
</tr>
<tr>
<td>05.15 pm - 05.30 pm</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>05.30 pm - 06.00 pm</td>
<td>High Tea</td>
<td></td>
</tr>
<tr>
<td>06.00 pm - 06.30 pm</td>
<td>Mala Talekar, USA</td>
<td>CAR-T Therapy for R/R Pediatric Leukaemias</td>
</tr>
<tr>
<td>06.30 pm - 07.00 pm</td>
<td>S D Banavali, Mumbai</td>
<td>Pediatric ALCL - Newer aspects</td>
</tr>
<tr>
<td>07.00 pm - 07.30 pm</td>
<td>Reena Nair, Kolkata</td>
<td>All lymphomas cannot be CHOPped</td>
</tr>
<tr>
<td>07.30 pm - 08.00 pm</td>
<td>Satya Dattatreya Palanky, Hyderabad</td>
<td>Obinutuzumab scores over Rituximab</td>
</tr>
<tr>
<td>08.00 pm - 08.15 pm</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>08.15 pm onwards</td>
<td>Dinner</td>
<td></td>
</tr>
</tbody>
</table>
### Scientific agenda

**Day 2 : Friday, 20th January 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Subject</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00 am - 08.45 am</td>
<td>Meet the professor</td>
<td>Multiple Myeloma (Ajay Nooka)</td>
</tr>
<tr>
<td>09.00 am - 09.30 am</td>
<td>Ajay Nooka, USA</td>
<td>Definition and management of high risk myeloma: progress in the last decade</td>
</tr>
<tr>
<td>09.30 am - 10.00 am</td>
<td>John Mascarenhas, USA</td>
<td>Ruxolitinib: The past, present and what to expect in the future</td>
</tr>
<tr>
<td>10.00 am - 10.30 am</td>
<td>Ghulam Mufti, London</td>
<td>Pathobiology of MDS - What is new ?</td>
</tr>
<tr>
<td>10.30 am - 10.45 am</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>10.45 am - 11.15 am</td>
<td>Coffee</td>
<td></td>
</tr>
<tr>
<td>11.15 am - 11.45 am</td>
<td>Flora Peyvandi, Italy</td>
<td>Bleeding disorders - Advances in treatment</td>
</tr>
<tr>
<td>11.45 am - 12.15 pm</td>
<td>A C Newland, London</td>
<td>How do I treat ITP in 2017 ?</td>
</tr>
<tr>
<td>12.15 pm - 12.45 pm</td>
<td>Sabine Eichinger, Vienna</td>
<td>Recurrent DVT - All that a clinician should know !</td>
</tr>
<tr>
<td>12.45 pm - 01.00 pm</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>01.00 pm - 01.45 pm</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>01.45 pm - 02.15 pm</td>
<td>Hasle Henrik, Denmark</td>
<td>Myelodysplastic and Myeloproliferative Disorders of Childhood</td>
</tr>
<tr>
<td>02.15 pm - 02.45 pm</td>
<td>Naval Daver, USA</td>
<td>The future of Hypomethylating Agents in AML: Building Optimal Combinations</td>
</tr>
<tr>
<td>02.45 pm - 03.15 pm</td>
<td>Hasle Henrik, Denmark</td>
<td>Management of childhood AML</td>
</tr>
<tr>
<td>03.15 pm - 03.30 pm</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>03.30 pm - 04.00 pm</td>
<td>Coffee</td>
<td></td>
</tr>
<tr>
<td>04.00 pm - 04.45 pm</td>
<td>Best of three abstracts, India</td>
<td></td>
</tr>
<tr>
<td>04.45 pm - 05.15 pm</td>
<td>Ghulam Mufti, London</td>
<td>Low risk MDS - What is new ?</td>
</tr>
<tr>
<td>05.15 pm - 05.45 pm</td>
<td>Ajay Nooka, USA</td>
<td>Newer Therapeutic options for R/R MM: focus on Carfilzomib</td>
</tr>
<tr>
<td>05.45 pm - 06.15 pm</td>
<td>John Mascarenhas, USA</td>
<td>Case based clinical approach to modern management of ET, PV &amp; PMF, as well as MPN related AML</td>
</tr>
<tr>
<td>06.15 pm - 06.30 pm</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>06.30 pm - 07.00 pm</td>
<td>High Tea</td>
<td></td>
</tr>
<tr>
<td>07.00 pm - 08.30 pm</td>
<td>Symposium : CML (Sponsors : BMS)</td>
<td></td>
</tr>
<tr>
<td>08.30 pm onwards</td>
<td>Dinner</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Speaker</td>
<td>Subject</td>
</tr>
<tr>
<td>------------------</td>
<td>------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>08.00 am - 08.45 am</td>
<td>Meet the professor</td>
<td>Platelets (A C Newland)</td>
</tr>
<tr>
<td>09.00 am - 09.30 am</td>
<td>A C Newland, London</td>
<td>A to Z about Romiplostim in the treatment of ITP</td>
</tr>
<tr>
<td>09.30 am - 10.00 am</td>
<td>Neal Young, USA</td>
<td>Eltrombopag as stem cell stimulator in marrow failure</td>
</tr>
<tr>
<td>10.00 am - 10.30 am</td>
<td>A C Newland, London</td>
<td>ASH-2016 updates in platelet disorders</td>
</tr>
<tr>
<td>10.30 am - 10.45 am</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>10.45 am - 11.15 am</td>
<td>Coffee</td>
<td></td>
</tr>
<tr>
<td>11.15 am - 11.45 am</td>
<td>Neal Young, USA</td>
<td>Telomere disease and other constitutional marrow failure syndromes in adults</td>
</tr>
<tr>
<td>11.45 am - 12.15 pm</td>
<td>Hasle Henrik, Denmark</td>
<td>Late complications in survivors of AML</td>
</tr>
<tr>
<td>12.15 pm - 12.45 pm</td>
<td>Navel Daver, USA</td>
<td>ASH-2016 updates in AML: Molecular and Immune Therapies</td>
</tr>
<tr>
<td>12.45 pm - 01.00 pm</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>01.00 pm - 01.45 pm</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>01.45 pm - 02.15 pm</td>
<td>John Mascarenhas, USA</td>
<td>ASH-2016 updates in MPN</td>
</tr>
<tr>
<td>02.15 pm - 02.45 pm</td>
<td>Ajay Nooka, USA</td>
<td>ASH-2016 updates in MM</td>
</tr>
<tr>
<td>02.45 pm - 03.15 pm</td>
<td>Ghulam Mufti, London</td>
<td>ASH-2016 updates in MDS</td>
</tr>
<tr>
<td>03.15 pm - 03.30 pm</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>03.30 pm - 04.00 pm</td>
<td>Closing ceremony</td>
<td>M B Agarwal, Swati Kanakia</td>
</tr>
<tr>
<td>04.00 pm</td>
<td>High Tea</td>
<td></td>
</tr>
</tbody>
</table>
Best of ASH-2016 & 21st Annual CME in Hematology

Know your faculty

1. Dr Adrian C Newland
   - Dr Adrian Newland is Professor of Haematology at Barts Health NHS Trust, London, UK and at Queen Mary University of London.
   - His clinical interests are in immune haematology and he jointly developed the National Registry for Immune Thrombocytopenia to collect comprehensive epidemiological and clinical data.
   - His group is undertaking research into the molecular and immune basis of autoimmune disease and he has an active clinical research programme in novel treatments.
   - He helped develop the ITP Clinical Network in the UK and he has developed guidelines and clinical studies in ITP.
   - He is Chair of the National Institute for Health and Care Excellence (NICE) Diagnostic Assessment Programme.
   - He is ex-President of the British Society for Haematology, was President of the Royal College of Pathologists from 2005–2008, and President of the International Society of Hematology (ISH) from 2016 - 2016.
   - He is Senior Editor of Hematology, the journal of the ISH, and he has published over 300 peer-reviewed papers in international journals including Blood, the British Journal of Haematology, The Lancet and the American Journal of Hematology.
   - He is current advisor to NHS England on pathology

2. Dr Henrik Hasle
   - He is professor in pediatric hematology/oncology at the department of Pediatrics, Aarhus University Hospital Skejby in Aarhus, Denmark.
   - He received his doctor of medicine degree from Odense University, Denmark.
   - He trained in epidemiology, hematology and pediatrics at Odense University Hospital, where he also completed a research fellowship in pediatric oncology with a thesis on myelodysplastic syndrome.
   - Since 2000, he was consultant and associate professor in pediatric hematology/oncology at Aarhus University Hospital Skejby in Aarhus Denmark and was subsequently awarded full professor in 2009.
   - He is a founding member of the European Working group on Myelodysplastic Syndromes in Childhood (EWOG-MDS) and served as chairman of the group 1998-2002.
   - He was the chairman of the AML group of the Nordic Society for Pediatric Hematology and Oncology (NOPHO) 2002 to 2010 and continues as responsible for the data managing of the NOPHO-AML protocols.
   - He is the chairman of the International-BFM-AML group from 2016.
   - He is the author or coauthor of more than 210 peer reviewed journal articles mainly dealing with myeloid leukemia in children, genetic predisposition to cancer, and late effects after cancer therapy.
3. **Dr John Mascarenhas**  
   He is an Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai (ISMMS) and a member of the Tisch Cancer Institute in New York City.
   - As a clinical investigator in malignant hematology with a focus in translational research involving Myeloproliferative Neoplasms (MPNs), he is primarily responsible for the clinical trials portion of the Myeloproliferative Disorders Program at ISMMS.
   - He is also the Principal Investigator (PI) of the clinical trials project within the National Cancer Institute sponsored Myeloproliferative Disorder Research Consortium (MPD-RC).
   - He has served as PI or Study Chair of multiple investigator-initiated and industry-sponsored early and late phase clinical trials evaluating innovative approaches to the treatment of MPNs.

4. **Dr Naval Daver**  
   - He is an Assistant Professor in the Department of Leukemia at MD Anderson Cancer Center in Houston, Texas.
   - He completed his medical school from Grant Medical College and Sir J J group of hospitals, Mumbai followed by a residency and fellowship in hematology-oncology from Baylor College of Medicine.
   - He has published more than 100 peer reviewed manuscripts focusing on emerging therapies and clinical trials in AML and myelofibrosis.
   - He is PI or Co-PI for over 25 ongoing multicenter or investigator initiated clinical trials with a focus in development of immune (Checkpoints, Vaccines, Monoclonals) and Molecular Therapies in AML and Myelofibrosis.
   - He is a member of the MDACC Hematology-Oncology Fellowship Steering committee and Course Director for the Leukemia Department.
   - He is a PI, Co-PI or collaborator on extramural grants including Leukemia Lymphoma Society Therapy Acceleration Program, Ladies Leukemia League, MDACC Leukemia SPORE, and MDACC CPRIT grant.
5. Dr Mala K Talekar

- She completed her medical school training from Grant Medical College & Sir JJ Group of Hospitals, Mumbai, India, with honors in 2001.

- She then did a residency in Pediatrics from Sir HN Hospital & Research Center, Mumbai, India with DCH and DNB certifications.

- Her passion to obtain advanced training in Pediatric Hematology Oncology led her to United States and after finishing a Pediatric residency from Children's Hospital of Philadelphia (CHOP) in 2011.

- She completed fellowship training in Pediatric Hematology Oncology & Bone Marrow Transplant at Penn State Hershey Children's Hospital in 2014.

- During her fellowship, the death of a teenaged patient due to a rare form of lymphoma despite multiple forms of treatment led her to pursue bench research evaluating TRAIL-based agents in hematologic malignancies.

- She found that a newly discovered small molecule TIC10 (now ONC201) could induce apoptotic death in a broad panel of lymphoma cell lines.

- Her early success helped her obtain prestigious research grants like American Society of Clinical Oncology (ASCO)'s Conquer Cancer Foundation's Young Investigator Award and Live Like Bella Childhood Cancer Foundation's Research funding to support her ongoing research for further drug development of this exciting molecule.

- She then joined the Children's Hospital of Philadelphia's Cancer Immunotherapy Frontier Program as an Attending Physician where she is an investigator on clinical trials evaluating Chimeric Antigen Receptor (CAR) Modified T Cell therapy in relapsed / refractory pediatric leukemias / lymphomas.

- Due to their unprecedented success, CAR-T based immunotherapies have been designated as a Novel Breakthrough Therapy for pediatric ALL and are on their way to potentially becoming the next standard of care for pediatric ALL.

- In a research role, she also actively pursues translational research in further developing the drug ONC201 for several pediatric cancers with a goal to bringing it to a clinical trial in pediatric malignancies.
6. Dr Genoveffa Franchini  
She is a renowned Retrovirologist who has pioneered research on oncogenes and human retroviruses (HTLVs and HIVs) at the Center of Cancer Research at the National Institute of Health, Bethesda, MD, USA.

- As a Chief of the Animal Models and Retroviral Vaccines Section, her lab has been working on HTLV-1 that causes leukemia and a progressive spastic myelopathy as well as in HIV pathogenesis and vaccine development using non-human primate models.

- One of the vaccines developed and tested in Dr. Franchini's laboratory is in clinical trials in 16,000 volunteers in Thailand. Dr. Franchini's laboratory genetically characterized SIV (Nature 1987) and defined the regulatory function of HIV-1/2 and SIV genes (Science 1986, 1990).

- Dr. Franchini serves the scientific field through editorial duties and has been an Associate Editor for Blood, Mucosal Immunology, and AIDS Reviews, and is in frequent demand to review manuscripts for journals including: Journal of Clinical Investigation, Journal of Experimental Medicine, Journal of Immunology, Journal of Infectious Diseases, Journal of Virology, Nature Medicine, Nature Reviews Immunology, Science and Oncogene.

- She serves on scientific committees, faculties, and advisory and review boards in intramural and extramural capacities.

- Dr. Franchini's major research interests are: (1) to investigate how HTLV-1 proteins subvert cellular and physiological pathways of T cells and lead to their transformation and (2) to develop strategies for preventive vaccines and therapeutic vaccines for HIV-1.
Dr. Flora Peyvandi

- She is Professor of Internal Medicine at the University of Milan and the Director of the Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.

- She received her medical degree from the University of Milan, Italy, is certified in Haematology and was awarded PhDs from the Maastricht University, The Netherlands and the University of Milan, Italy for her research in the field of rare bleeding disorders.

- Her basic and medical science research has focused on the investigation of coagulation disorders.

- Her research in the prevalence and mechanism of coagulation disorders aims at developing cost-effective treatment for the widespread treatment of patients.

- She has authored and co-authored more than 310 scientific publications that have been published across well-known specialized journals (IF of about 1600, H index WoS of 43) and also 18 chapters in various books.

- Since 1999, she has been invited as an expert speaker at more than 100 national and international meetings and congresses.

- She has been the successful recipient of more than 40 project grants funded by Italian and International organizations and she was the principal investigator of the Establishment of an European Network of Rare Bleeding Disorders programme.

- She participates in clinical, educational and research activities in different parts of the world and she was Chair of the International Society of Thrombosis and Haemostasis (ISTH) Scientific and Standardization Committee on Factor VIII, Factor IX and Rare Coagulation Disorders.

- She is member of the ISTH council, member of the Executive Committee of the World Federation of Hemophilia (WFH), member of the executive committee of the European Association for Haemophilia and Allied Disorders (EAHAD) and member of the Medical Advisory Group of the European Hemophilia Consortium (EHC).

- In 2014 she was awarded the "Great Hippocrates " that is delivered to Italian medical researcher of the year.
知道您的教授

8. Dr. Sabine Eichinger

- 她在维也纳大学医学部第I部和哈佛医学院贝思以色列医院接受了医学和科学训练。
- 她是维也纳大学医院医学部的副教授，也是抗凝血病房的负责人。
- 她在血栓形成和凝血领域有广泛的经验，并且是一位设计和执行临床研究的专家。
- 她有坚实的经验，用于研究促凝血剂和抗凝血剂的作用机制以及评估风险因素和生物标志物在血栓性疾病中的作用。
- 她作为抗凝血患者的若干干预性研究的主要研究者。
- 她曾担任国际血栓症和血友病学会科学和标准化委员会的过去主席，也曾经是该学会的理事。
- 她是若干国际和国内学术奖项的获得者。

9. Dr. Neal Young

- Dr. Young 是美国心脏、肺和血液研究所的血液学分部的首席。
- 他毕业于哈佛大学和约翰霍普金斯医学院。
- 他在麻省总医院进行了医学住院，并在圣路易斯的华盛顿大学进行了血液学培训。
- 博士后奖学金在生物化学和分子生物学，分别在国立卫生研究院，由Alan Schecter和Arthur Nienhuis教授。
- 他的研究兴趣包括骨髓衰竭、正常和异常造血、病毒性感染的骨髓细胞、自身免疫以及基因组不稳定性和白血病的机制。
- 他的工作包括在贝斯的骨髓衰竭病房的临床试验（免疫抑制，端粒修饰，干细胞刺激），基本科学在病毒学，免疫学，和细胞生物学（parvovirus B19，端粒酶基因突变，免疫病理学），以及流行病学（泰国最大人群血友病的研究）。
- 他发表了近400篇原始研究文章，超过150篇评论和章节，以及10本专著。
- 他的实验室已经培训了几十位世界一流的血液学专家。
Abstracts are invited for poster presentation during Best of ASH-2016. Please note that these will be e-Posters. Following are the guidelines for the same:

- An e-Poster is an electronic version of a poster presentation.
- The e-Poster presentations must be prepared in PowerPoint.
- As an e-Poster presenter you are asked to prepare a PowerPoint presentation up to a maximum of 08 slides.
- It may include text, figures, charts, tables, images, and artwork but an e-Poster digital presentation does not include any audio, video or animation.
- Do not use special fonts which are not part of the standard PowerPoint package as this will cause problems while uploading your file.
- Set the slide size of the page to “On-screen show” and landscape orientation in the page set-up section.
- Portrait orientation will not be displayed properly.
- Three best abstracts will be invited to do oral presentation.
- Last date for receiving abstract of the poster is Thursday, 15th December 2016.

Recommended Format:

- **Slide 1**: Title + Authors
- **Slide 2**: Introduction
- **Slide 3**: Objectives
- **Slide 4**: Materials & Methods
- **Slide 5 - 7**: Results
- **Slide 8**: Conclusions
Registration fee

<table>
<thead>
<tr>
<th>Category</th>
<th>Up to 31st December 2016</th>
<th>Spot Registration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fellow / Trainee / Resident</td>
<td>₹ 9000 /-</td>
<td>₹ 21000 /-</td>
</tr>
<tr>
<td>All other delegates</td>
<td>₹ 11000 /-</td>
<td>₹ 21000 /-</td>
</tr>
</tbody>
</table>

All registrations after 31st December 2016 will be considered as spot registrations.

Note:
- Registration is mandatory for all participants.
- Registrations will be restricted to first 150 delegates.
- Registration fee includes lunch on all 3 days.

Accommodation

Accommodation is available at Hotel ITC Grand Central, Parel, Mumbai which is the venue of the meeting. It will be available only for 2 nights i.e. from 12 noon on Thursday, 19th January 2017 to 12 noon on Saturday, 21st January 2017.

There are 2 options:

a) Single room, single occupancy: ₹ 13,000/- per night.
b) Double room, double occupancy: ₹ 15,000/- per night.

Note: For double room - double occupancy, delegates have to forward 2 names themselves.

All payments are to be made in favour of: Mumbai Hematology Group

Refund policy

Refunds towards registration will be done only until 15th December 2016 after deducting 50% towards administrative charges. Refunds towards accommodation will be done after deducting one day hotel stay charges. The refunds will be done only on receipt of email indicating the same and one month after the conference is over.

Online registration

For online registration, you can go to the following link:
http://in.eregnow.com/ticketing/register/ASH2016ANNUALCME

Address for all correspondence:
Dr M B Agarwal, Course coordinator,
Best of ASH-2016
Mumbai Hematology Group
Hematology Clinic, Ghamat Lodge, 804-A,
Dr B Ambedkar Road, Dadar TT, Mumbai 400014, India.
Cell: +91 9820024850,
Email ID: mbagarwal1@hotmail.com
mhgpho@hotmail.com
Website: www.bestofash2016.com

Event Manager:
Nucleus
Mr. Rajesh Sharma: +91 9374073512
Mr. Yash Agarwal: +91 8790612727
Mr. Kalpesh Pambhar: +91 9601608846